Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

This is a correction to: Wail Alqatta, Surgical management of giant splenomegaly in chronic myeloid leukemia: a challenging splenectomy case, Journal of Surgical Case Reports, Volume 2025, Issue 7, July 2025, rjaf485, https://doi.org/10.1093/jscr/rjaf485

In the originally published version of this manuscript, references 3, 4, 7 and 10 were incorrect and were mistakenly listed as follows:

3. Iannitto E,Tripodo C. Splenic marginal zone lymphoma. Hematol Oncol 2005;23:55–66.

4. Tefferi A. Splenomegaly in myeloproliferative disorders: clinical features and therapeutic options. Blood Rev 2005;19:273–86.

7. Tefferi A, Elliott MA, Pardanani A, et al. Splenectomy in patients with chronic myeloid leukemia or myeloproliferative diseases: outcomes, complications, and prognostic implications. Blood 2007;110:2553. https://doi.org/10.1182/blood.V110.11.2553.2553

10. Yeung DT, Osborn MP, White DL, et al. Combination of large spleen size and low in vivo kinase inhibition is an early predictor of inferior molecular response and poor outcomes in chronic myeloid leukemia. Blood Cancer J 2017;7:e540.

This has been corrected, and the references in the published article have been updated as follows:

3. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140:1200–28. https://doi.org/10.1182/blood.2022015850

4. Chapman J, Goyal A, Azevedo AM. Splenomegaly [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan– [updated 2023 Jun 26; cited 2025 Jul 8]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430907/

7. Tam CS, Pollock RE, Manning J, et al. Splenectomy in patients with chronic myeloid leukemia or myeloproliferative diseases: outcomes, complications and prognostic implications. Blood 2007;110:2553. https://doi.org/10.1182/blood.V110.11.2553.2553

10. Kok C, Saunders V, Dang P, et al. Combination of large spleen and low in vivo kinase inhibition is an early predictor of inferior molecular response and poor outcomes in chronic myeloid leukaemia. HemaSphere. 2023;7:e907256e. https://doi.org/10.1097/01.HS9.0000967516.90725.6e

© The Author(s) 2026. Published by Oxford University Press and JSCR Publishing Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Issue Section:
Correction
Download all slides